141 related articles for article (PubMed ID: 25270285)
21. Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection.
Liu X; Yu L; Han C; Lu S; Zhu G; Su H; Qin W; Liao X; Peng T
Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):739-747. PubMed ID: 27288300
[TBL] [Abstract][Full Text] [Related]
22. PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study.
Yamamoto M; Kobayashi T; Mashima H; Miki D; Kuroda S; Hamaoka M; Aikata H; Chayama K; Ohdan H
Int J Surg; 2020 Aug; 80():84-90. PubMed ID: 32615319
[TBL] [Abstract][Full Text] [Related]
23. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
Zayed SA; Zahran NM; Khorshied MM; Abdel-Aziz AO; Mahmoud O; Morsy SA; Shousha HI; Elbaz TM; Nabeel MM; Harb ARK
J Med Virol; 2019 Aug; 91(8):1537-1544. PubMed ID: 30945308
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
25. Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development.
Chen TP; Lee HL; Huang YH; Hsieh MJ; Chiang WL; Kuo WH; Chou MC; Yang SF; Yeh CB
Tumour Biol; 2016 Feb; 37(2):2067-74. PubMed ID: 26341495
[TBL] [Abstract][Full Text] [Related]
26. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization.
Liu J; Wang D; Zhou J; Wang L; Zhang N; Zhou L; Zeng J; Liu J; Yang M
Arch Toxicol; 2021 May; 95(5):1621-1629. PubMed ID: 33713148
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Wu YS; Bao DK; Dai JY; Chen C; Zhang HX; Yang Y; Xing JL; Huang XJ; Wan SG
Asian Pac J Cancer Prev; 2015; 16(3):1051-6. PubMed ID: 25735330
[TBL] [Abstract][Full Text] [Related]
29. Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population.
Wang PS; Kuai J; Li H; Wang CG; Shi BJ; Zhong L
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):282-8. PubMed ID: 27298104
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
31. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma.
Liu F; Luo L; Liu Z; Wu S; Zhang W; Li Q; Peng Y; Wei Y; Li B
Mol Carcinog; 2020 Nov; 59(11):1243-1255. PubMed ID: 32869896
[TBL] [Abstract][Full Text] [Related]
32. Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocelluar Carcinoma.
Ge NJ; Shi ZY; Yu XH; Huang XJ; Wu YS; Chen YY; Zhang J; Yang YF
Asian Pac J Cancer Prev; 2015; 16(9):4103-7. PubMed ID: 25987094
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.
Lautem A; Simon F; Hoppe-Lotichius M; Mittler J; Vollmar J; Schad A; Düber C; Galle PR; Otto G; Zimmermann T; Lang H
Oncol Rep; 2019 Apr; 41(4):2299-2310. PubMed ID: 30720132
[TBL] [Abstract][Full Text] [Related]
34. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma.
Nishikawa H; Osaki Y; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Henmi S; Sakamoto A; Ishikawa T; Saito S; Kita R; Kimura T
World J Gastroenterol; 2012 Mar; 18(12):1379-84. PubMed ID: 22493552
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
36. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
[TBL] [Abstract][Full Text] [Related]
37. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
[TBL] [Abstract][Full Text] [Related]
38. [The relationship between gene polymorphism of telomerase reverse transcriptase and susceptibility to hepatocellular carcinoma].
Ding CY; Hu LM; Hu ZB; Shen HB
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jul; 45(7):593-6. PubMed ID: 22041560
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
